Article
Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations.
Genes, chromosomes & cancer - 1 Jul 2012
Thol Felicitas, Kölking Britta, Damm Frederik, Reinhardt Katarina, Klusmann Jan-Henning, Reinhardt Dirk, von Neuhoff Nils, Brugman Martijn H, Schlegelberger Brigitte, Suerbaum Sebastian, Krauter Jürgen, Ganser Arnold, Heuser Michael
Abstract excerpt
Systematic assessment of minimal residual disease (MRD) in acute myeloid leukemia (AML) patients has been hampered by lack of a reliable, uniform MRD marker applicable to all patients. We evaluated next-generation sequencing (NGS) for MRD assessment in AML patients (n = 80 samples). The ability of NGS technologies to generate thousands of clonal sequences makes it possible to determine the allelic ratio of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.